PE20141038A1 - Sales de 2,3-dihidroimidazo[1,2-c]quinazolina substituida - Google Patents

Sales de 2,3-dihidroimidazo[1,2-c]quinazolina substituida

Info

Publication number
PE20141038A1
PE20141038A1 PE2013002186A PE2013002186A PE20141038A1 PE 20141038 A1 PE20141038 A1 PE 20141038A1 PE 2013002186 A PE2013002186 A PE 2013002186A PE 2013002186 A PE2013002186 A PE 2013002186A PE 20141038 A1 PE20141038 A1 PE 20141038A1
Authority
PE
Peru
Prior art keywords
dihydroimidazo
salt
substituted salts
quinazoline substituted
referred
Prior art date
Application number
PE2013002186A
Other languages
English (en)
Inventor
Jan Georg Peters
Hans-Christian Militzer
Hartwig Muller
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43984137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141038(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of PE20141038A1 publication Critical patent/PE20141038A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDO A UNA SAL DE DICLORHIDRATO DE 2-AMINO-N-[7-METOXI-8-(3-MORFOLIN-4-ILPROPOXI)-2,3-DIHIDROIMIDAZO[1,2-c]QUINAZOLIN-5-IL]PIRIMIDIN-5-CARBOXAMIDA, UN SOLVATO, HIDRATO O TAUTOMERO DE LA MISMA. SE REFIERE TAMBIEN A UN METODO DE PREPARACION DE DICHA SAL QUE COMPRENDE: AGREGAR ACIDO CLORHIDRICO A UN COMPUESTO DE FORMULA (I) PREFERENTEMENTE EN SUSPENSION, FORMANDOSE DICHA SAL. REFERIDO ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHA SAL ES UTIL PARA EL TRATAMIENTO Y/O PROFILAXIS DEL CANCER
PE2013002186A 2011-04-05 2012-03-29 Sales de 2,3-dihidroimidazo[1,2-c]quinazolina substituida PE20141038A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11161111A EP2508525A1 (en) 2011-04-05 2011-04-05 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts

Publications (1)

Publication Number Publication Date
PE20141038A1 true PE20141038A1 (es) 2014-09-05

Family

ID=43984137

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002186A PE20141038A1 (es) 2011-04-05 2012-03-29 Sales de 2,3-dihidroimidazo[1,2-c]quinazolina substituida

Country Status (42)

Country Link
US (2) US10383876B2 (es)
EP (2) EP2508525A1 (es)
JP (2) JP5763834B2 (es)
KR (1) KR101937501B1 (es)
CN (1) CN103649091B (es)
AP (1) AP3709A (es)
AR (1) AR085718A1 (es)
AU (1) AU2012238891B2 (es)
BR (1) BR112013025549A2 (es)
CA (1) CA2832123C (es)
CL (1) CL2013002870A1 (es)
CO (1) CO6781534A2 (es)
CR (1) CR20130511A (es)
CU (1) CU24208B1 (es)
CY (1) CY1116231T1 (es)
DK (1) DK2694508T3 (es)
DO (1) DOP2013000223A (es)
EA (1) EA023646B1 (es)
EC (1) ECSP13013006A (es)
ES (1) ES2529653T3 (es)
GT (1) GT201300234A (es)
HK (1) HK1195907A1 (es)
HR (1) HRP20150138T1 (es)
IL (1) IL228561A (es)
JO (1) JO2958B1 (es)
MA (1) MA35014B1 (es)
ME (1) ME02021B (es)
MX (1) MX336057B (es)
MY (1) MY169452A (es)
PE (1) PE20141038A1 (es)
PL (1) PL2694508T3 (es)
PT (1) PT2694508E (es)
RS (1) RS53811B1 (es)
SG (1) SG193595A1 (es)
SI (1) SI2694508T1 (es)
SM (1) SMT201500037B (es)
TN (1) TN2013000401A1 (es)
TW (2) TWI592158B (es)
UA (1) UA111604C2 (es)
UY (1) UY33985A (es)
WO (1) WO2012136553A1 (es)
ZA (1) ZA201307105B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
UA122822C2 (uk) 2013-04-08 2021-01-06 Байєр Фарма Акцієнгезелльшафт ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ
CA2915311A1 (en) 2013-06-14 2014-12-18 Bayer Pharma Aktiengesellschaft Anti-tweakr antibodies and uses thereof
CN103694319B (zh) * 2013-12-20 2018-02-27 深圳翰宇药业股份有限公司 一种布舍瑞林的纯化方法
EP3018127A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018131A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
CA2978830A1 (en) 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
CA2978807A1 (en) * 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
TWI719969B (zh) 2015-03-23 2021-03-01 德商拜耳製藥股份有限公司 抗-ｃｅａｃａｍ６抗體及其用途
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
CA3012890A1 (en) 2016-02-01 2017-08-10 Bayer Pharma Aktiengesellschaft Copanlisib biomarkers
SG10202007322PA (en) 2016-02-01 2020-09-29 Bayer Pharma AG Copanlisib biomarkers
SG10202007520WA (en) 2016-03-02 2020-09-29 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use
US10844066B2 (en) 2016-03-08 2020-11-24 Bayer Pharma Aktiengesellschaft 2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
US10925880B2 (en) 2016-09-23 2021-02-23 Bayer Pharma Aktiengesellschaft Combination of PI3K-inhibitors
WO2018112176A1 (en) 2016-12-14 2018-06-21 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof
EP3585437B1 (en) 2017-02-24 2022-12-21 Bayer Pharma Aktiengesellschaft Combinations of copanlisib with anti-pd-1 antibody
WO2019002068A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag COMBINATION OF A PI3K INHIBITOR AND AN ANDROGEN RECEPTOR ANTAGONIST
IL272857B2 (en) * 2017-09-08 2024-03-01 Bayer Consumer Care Ag Cofanalisib formulations
EP3498266A1 (en) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
WO2019105734A1 (en) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
WO2019197269A1 (en) 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
US20210187134A1 (en) 2018-08-28 2021-06-24 Bayer As Combination of pi3k-inhibitors and targeted thorium conjugates
EP3866805A1 (en) 2018-10-16 2021-08-25 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
WO2020079079A1 (en) 2018-10-17 2020-04-23 Sandoz Ag Co-crystals comprising levothyroxine and a dicarboxylic acid
EP3903786A4 (en) * 2018-12-27 2022-09-28 Holosmedic NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION TO INCREASE ANTI-CANCER ACTIVITY
WO2020164997A1 (en) 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
WO2023218032A1 (en) 2022-05-13 2023-11-16 Synthon B.V. Solid forms of copanlisib salts

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH605550A5 (es) 1972-06-08 1978-09-29 Research Corp
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
GB0021865D0 (en) 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
UA82205C2 (en) 2002-09-30 2008-03-25 Байер Фармасьютикалз Корпорейшн Fused azole-pyrimidine derivatives
JP4323793B2 (ja) 2002-12-16 2009-09-02 キヤノン株式会社 ズームレンズ及びそれを有する光学機器
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
JP5620275B2 (ja) 2008-01-14 2014-11-05 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 超増殖性疾患及び脈管形成に関連する疾病を処理するために有用なスルホン置換された２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン誘導体類
EP2168583A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2168582A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
CA2796253A1 (en) 2010-04-16 2011-10-20 Bayer Intellectual Property Gmbh Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
UA122822C2 (uk) 2013-04-08 2021-01-06 Байєр Фарма Акцієнгезелльшафт ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ
CA2932221C (en) 2013-12-03 2022-02-22 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
CA2978807A1 (en) * 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
CA2978830A1 (en) 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations

Also Published As

Publication number Publication date
CR20130511A (es) 2013-12-04
EP2694508B1 (en) 2014-11-19
KR20140021637A (ko) 2014-02-20
WO2012136553A1 (en) 2012-10-11
ME02021B (me) 2015-05-20
JO2958B1 (en) 2016-03-15
SI2694508T1 (sl) 2015-03-31
GT201300234A (es) 2015-01-16
SG193595A1 (en) 2013-10-30
US10383876B2 (en) 2019-08-20
CY1116231T1 (el) 2017-02-08
ZA201307105B (en) 2014-11-26
JP5826961B2 (ja) 2015-12-02
SMT201500037B (it) 2015-05-05
TWI592158B (zh) 2017-07-21
CA2832123A1 (en) 2012-10-11
MY169452A (en) 2019-04-11
MX336057B (es) 2016-01-07
PT2694508E (pt) 2015-02-10
MA35014B1 (fr) 2014-04-03
ES2529653T3 (es) 2015-02-24
CN103649091A (zh) 2014-03-19
HK1195907A1 (zh) 2014-11-28
JP5763834B2 (ja) 2015-08-12
IL228561A (en) 2015-10-29
JP2014510119A (ja) 2014-04-24
AP3709A (en) 2016-05-31
TW201637656A (zh) 2016-11-01
RS53811B1 (en) 2015-06-30
TW201249847A (en) 2012-12-16
TWI549954B (zh) 2016-09-21
TN2013000401A1 (en) 2015-03-30
EA201391470A1 (ru) 2014-03-31
BR112013025549A2 (pt) 2016-12-27
EP2508525A1 (en) 2012-10-10
CO6781534A2 (es) 2013-10-31
EA023646B1 (ru) 2016-06-30
CU24208B1 (es) 2016-11-29
MX2013011583A (es) 2013-12-16
EP2694508A1 (en) 2014-02-12
CA2832123C (en) 2018-09-11
JP2015164936A (ja) 2015-09-17
DK2694508T3 (en) 2015-02-16
AU2012238891B2 (en) 2016-12-01
PL2694508T3 (pl) 2015-04-30
NZ616198A (en) 2015-09-25
CU20130133A7 (es) 2014-01-29
CL2013002870A1 (es) 2014-06-20
HRP20150138T1 (hr) 2015-05-08
AU2012238891A1 (en) 2013-10-24
ECSP13013006A (es) 2013-12-31
DOP2013000223A (es) 2013-11-15
IL228561A0 (en) 2013-12-31
UY33985A (es) 2012-10-31
AP2013007219A0 (en) 2013-10-31
US9636344B2 (en) 2017-05-02
UA111604C2 (uk) 2016-05-25
US20160193219A1 (en) 2016-07-07
US20140072529A1 (en) 2014-03-13
AR085718A1 (es) 2013-10-23
CN103649091B (zh) 2016-06-22
KR101937501B1 (ko) 2019-01-10

Similar Documents

Publication Publication Date Title
PE20141038A1 (es) Sales de 2,3-dihidroimidazo[1,2-c]quinazolina substituida
BR112014005226A2 (pt) derivados de benzonitrila como inibidores de cinase
PH12016501204A1 (en) Syk inhibitors
PH12015501965A1 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
BR112015028501B8 (pt) Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico
NZ711424A (en) Pyridine derivatives as soft rock inhibitors
EA201491671A1 (ru) Гетероциклильные соединения
AR084469A1 (es) Combinaciones de inhibidores de quinasas para el tratamiento del cancer
PH12015501585A1 (en) Manufacturing process for pyrimidine derivatives
PE20151412A1 (es) Derivados de pirimidin-2,4-diamina para el tratamiento de cancer
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA202192151A1 (ru) Применение пиразолпиримидиновых производных для лечения нарушений, связанных с pi3k
MD20160017A2 (ro) Polimorf al inhibitorilor SYK
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
EA201390917A1 (ru) Дигетероарильные соединения в качестве ингибиторов vps34
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
BR112014005389A8 (pt) Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal
MX2015013328A (es) Uso de antagonistas del receptor de ep4 en el tratamiento de enfermedad de cartilago.
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2
AR083575A1 (es) Aminopirazoles para inhibir la proteinquinasa chk1
EA201391820A1 (ru) Гетероциклические сульфонамидные производные
SG11201903463PA (en) Quinolyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition of the same, and use of the same
EA201491878A8 (ru) Замещенные ксантиновые производные
EA201591487A1 (ru) Производные замещенной бисфенилбутановой кислоты в качестве ингибиторов nep с улучшенной in vivo эффективностью
TN2013000094A1 (en) Manufacturing process for pyrimidine derivatives

Legal Events

Date Code Title Description
FG Grant, registration